COSCIENS Biopharma Inc.
CSCI · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 83.8% | -55% | 77.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 35.4% | 29.5% | 61.7% | 44.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -86.9% | -217.3% | -157.6% | -286.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -98.3% | -243.7% | -202.6% | -307.6% |
| EPS Diluted | -0.85 | -1.16 | -2.35 | -1.85 |
| % Growth | 26.7% | 50.6% | -27% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |